Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib Combined With Fenestration Decompression for BRAF Mutant Ameloblastoma
NCT06264778Phase 3Not yet recruiting
- Sponsor
- Shandong University
- Start
- Mar 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dabrafenib + trametinib in ameloblastoma, sponsored by Shandong University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
dabrafenib + trametinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on NCT06264778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264778.